How much does it cost to bootstrap a gene therapy startup? Not too much if you're Jim Wilson, per Passage Bio's $125M IPO filing
Days ago when Deerfield partner Bruce Goldsmith jumped to helm Passage Bio, he cited a few reasons why it’s an “extremely exciting time” to be joining the gene therapy player: IND filings for three lead programs, a data-rich 2021 and an expanding pipeline of experimental drugs for rare, monogenic CNS diseases.
It turns out there’s one more reason he held back: The Philadelphia-based startup was prepping an IPO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.